A Perspective On Shire plc’s Successful Specialty Business Model: Rare Diseases And Orphan Drugs
An Internet article that provides an interesting perspective on Shire plc’s successful specialty business model – rare diseases and orphan drugs, I am sharing with readers. Many large biotechnology and pharmaceutical companies are buying smaller companies who have a niche in the rare disease and orphan drug market.
In light of all of the recent publicity of Shire plc’s Vpriv verses Genzyme’s Cerezyme in the Gaucher Disease market, this article provides an interesting perspective :
CurrentPartnering.com July 31, 2012 Article titled, “Shire Takes Its Specialty Seriously”.